Posted March 29, 2012 by drugwatch A Johnson & Johnson-brand transvaginal mesh that was used for more than three years before U.S. regulators approved it is now the subject of court claims from women who were injured by it, Bloomberg News reported. The Gynecare Prolift, made by Johnson & Johnson’s Ethicon unit, was introduced to Full Article…
Search LawsuitInformation.org
Viewing 1 to 6 of 6 items
Drug Approvals Up for 2011
Posted January 9, 2012 by The Scientist The FDA approved 30 drugs last year, the highest number in the last 7 years. The US Food and Drug Administration approved 30 drugs in 2011, compared with 21 in 2010, according to an analysis by Bloomberg News. That number is the highest since 36 drugs were approved Full Article…
Comments Off
Avandia Injury Lawsuit Settlement Negotiations Continue
Posted November 10, 2011 by About Lawsuits The federal judge presiding over all Avandia lawsuits is pushing further settlement negotiations between GlaxoSmithKline and plaintiffs in all remaining injury cases, indicating that cases will be set for trial if the vast majority of the lawsuits are not settled within the next three months. U.S. District Judge Full Article…
Comments Off
Settlement of Avandia Lawsuits Reached in About 10,000 More Cases
Posted July 13, 2010 by AboutLawsuits.com GlaxoSmithKline has reportedly agreed to pay $460 million to settle Avandia lawsuits filed by about 10,000 more people. The agreement comes as two FDA advisory committees have begun meeting to debate whether the controversial diabetes drug should be recalled from the market. The Avandia settlement was leaked to Bloomberg Full Article…
Comments Off
Glaxo Paxil Birth Defects Settlements Total $1 Billion
Posted July 22, 2010 on Parker Waichman Alonso GlaxoSmithKline (GSK) has agreed to pay in excess of $1 billion to settle hundreds of lawsuits over claims of birth defects linked to Paxil, said Fierce Pharma. The $1 billion is from the drug maker’s $2.4 billion legal expense budget and will pay about $1.2 million to Full Article…
Comments Off
Glaxo Memo Suggested Burying Paxil Birth Defect Evidence
Posted February 15, 2010 on Carey & Danis Worried that animal studies would link the antidepressant Paxil with birth defects, an executive with the drug’s maker, GlaxoSmithKline, suggested burying the evidence, Bloomberg News reports. Written in 1997, the memo urged scientists to withhold information about the birth defect risks the drug posed to pregnant women. Full Article…
Comments Off
